Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jul 1;307(1):F116-21.
doi: 10.1152/ajprenal.00111.2014. Epub 2014 May 7.

First D1-like receptor PET imaging of the rat and primate kidney: implications for human disease monitoring

Affiliations

First D1-like receptor PET imaging of the rat and primate kidney: implications for human disease monitoring

Michael L Granda et al. Am J Physiol Renal Physiol. .

Abstract

The intrarenal dopamine system is important for signaling and natriuresis, and significant dysfunction is associated with hypertension and kidney disease in ex vivo studies. Dopamine receptors also modulate and are modulated by the renin-angiotensin-aldosterone system. Here, we show the first in vivo measurement of D1-like receptors in the renal cortex of Sprague-Dawley rat and Papio anubis baboon using [(11)C]NNC 112, a positron emission tomography radioligand for D1-like receptors. In addition, we show a D1-like binding potential response to angiotensin II blockade in rats using losartan. Demonstration of self-saturable binding in the rat as well as specific and saturable binding in Papio anubis validate the use of [(11)C]NNC 112 in the first in vivo measurement of renal dopamine D1-like receptors. Furthermore, [(11)C]NNC 112 is a radioligand tool already validated for use in probing human central nervous system (CNS) D1-like receptors. Our work demonstrates specific and saturable non-CNS binding in higher animals and the ability to quantify physiological response to drug treatment and provides a clear path to extend use of [(11)C]NNC 112 to study renal dopamine in humans.

Keywords: dopamine; hypertension; positron emission tomography; renal PET; renal dopamine.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Time activity curve of [11C]NNC 112 in rat. Pretreatment with unlabeled NNC 112 reduces binding (77%).
Fig. 2.
Fig. 2.
A: simultaneous magnetic resonance-positron emission tomography with [11C]NNC 112 in Papio anubis showing high renal cortex uptake at early time points. B: time activity curve of [11C]NNC 112 in drug naive and SCH-23390-pretreated animal. C: volume of distribution of [11C]NNC 112 baseline and pretreated with SCH-23390. D: time activity curves for other peripheral organs in Papio anubis. E: peripheral organ time activity curves in SCH-23390-pretreated animal showing no evidence of specific D1-like binding, increased biliary excretion.
Fig. 3.
Fig. 3.
Standardized uptake value of [11C]NNC 112 in drug naive (n = 2) or losartan-pretreated rats showing short-term potentiation of D1-like binding. Binding of [11C]NNC 112 is increased by 31% at 30 min (P = 0.025, n = 4), but is not significantly different than baseline at 1 h postinjection (P = 0.878, n = 3).

Similar articles

Cited by

  • Dopamine D1R Receptor Stimulation as a Mechanistic Pro-cognitive Target for Schizophrenia.
    Abi-Dargham A, Javitch JA, Slifstein M, Anticevic A, Calkins ME, Cho YT, Fonteneau C, Gil R, Girgis R, Gur RE, Gur RC, Grinband J, Kantrowitz J, Kohler C, Krystal J, Murray J, Ranganathan M, Santamauro N, Van Snellenberg J, Tamayo Z, Wolf D; TRANSCENDS Group; Gray D, Lieberman J. Abi-Dargham A, et al. Schizophr Bull. 2022 Jan 21;48(1):199-210. doi: 10.1093/schbul/sbab095. Schizophr Bull. 2022. PMID: 34423843 Free PMC article.
  • Neuroinflammatory component of gray matter pathology in multiple sclerosis.
    Herranz E, Giannì C, Louapre C, Treaba CA, Govindarajan ST, Ouellette R, Loggia ML, Sloane JA, Madigan N, Izquierdo-Garcia D, Ward N, Mangeat G, Granberg T, Klawiter EC, Catana C, Hooker JM, Taylor N, Ionete C, Kinkel RP, Mainero C. Herranz E, et al. Ann Neurol. 2016 Nov;80(5):776-790. doi: 10.1002/ana.24791. Epub 2016 Oct 25. Ann Neurol. 2016. PMID: 27686563 Free PMC article.
  • Characterization of cortico-meningeal translocator protein expression in multiple sclerosis.
    Herranz E, Treaba CA, Barletta VT, Mehndiratta A, Ouellette R, Sloane JA, Ionete C, Babu S, Mastantuono M, Magon S, Loggia ML, Makary MM, Hooker JM, Catana C, Kinkel RP, Nicholas R, Klawiter EC, Magliozzi R, Mainero C. Herranz E, et al. Brain. 2024 Jul 5;147(7):2566-2578. doi: 10.1093/brain/awae030. Brain. 2024. PMID: 38289855 Free PMC article.
  • Antihypertensive mechanisms of intra-renal dopamine.
    Zhang MZ, Harris RC. Zhang MZ, et al. Curr Opin Nephrol Hypertens. 2015 Mar;24(2):117-22. doi: 10.1097/MNH.0000000000000104. Curr Opin Nephrol Hypertens. 2015. PMID: 25594544 Free PMC article. Review.

References

    1. Abrams AC. Clinical Drug Therapy: Rationales for Nursing Practice (8th ed.). Philadelphia: Lippincott Williams & Wilkins, 2007.
    1. Albrecht FE, Drago J, Felder RA, Printz MP, Eisner GM, Robillard JE, Sibley DR, Westphal HJ, Jose PA. Role of the D1A dopamine receptor in the pathogenesis of genetic hypertension. J Clin Invest 97: 2283–2288, 1996. - PMC - PubMed
    1. Aperia AC. Intrarenal dopamine: a key signal in the interactive regulation of sodium metabolism. Annu Rev Physiol 62: 621–647, 2000. - PubMed
    1. Armando I, Villar VAM, Jose PA. Dopamine and renal function and blood pressure regulation. Compr Physiol 1: 1075–1117, 2011. - PMC - PubMed
    1. Bourne JA. SCH 23390: the first selective dopamine D1-like receptor antagonist. CNS Drug Rev 7: 399–414, 2001. - PMC - PubMed

LinkOut - more resources